IQVIA™ Real-World Insights Bibliography

High?Expenditure Disease in the EU?28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?
Author(s): Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid, Tom Vandebrouck
Affiliations(s): Department for Health Economics, Bielefeld University, Bielefeld, Germany; IQVIA Ltd, HEOR, London, UK; Novo Nordisk Region Europe Pharmaceuticals A/S, Copenhagen, Denmark; Novo Nordisk Region Europe Pharmaceuticals A/S, Brussels, Belgium
Publication(s):  PharmacoEconomics-Open. 2021 Jan; doi.org/10.1007/s41669-020-00253-4
Document Type(s): Article,
Countries: Europe,
Click here for the abstract
C:
Y:
Diabetes, Health economics, Oncology,
2021
  L:
A:
English
Burden of illness, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Quality of life, Retrospective database analysis, Review,
  Add to report
 
 
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Author(s): Lars Holger Ehlers 1, Mark Lamotte 2, Sofia Monteiro 3, Susanne Sandgaard 4, Pia Holmgaard 4, Evan C Frary 4, Niels Ejskjaer 5 6 7
Affiliations(s): 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 2IQVIA Real World Solutions, Zaventem, Belgium. 3IQVIA Real World Solutions, London, UK. 4Boehringer Ingelheim Danmark A/S, København Ø, Hovedstaden, Denmark. 5Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. n.ejskjaer@rn.dk. 6Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. 7Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk.
Publication(s):  Diabetes Therapy https://doi.org/10.1007/s13300-021-01040-y
IQVIA HEOR Zaventem Brussels
PMID: 33856655 PMCID: PMC8099952 DOI: 10.1007/s13300-021-01040-y
Document Type(s): 
Countries: Denmark,
Click here for the abstract
C:
Y:
Diabetes, Health economics,
2021
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China
Author(s): Ahmed Salem 1, Peng Men 2 3, Mafalda Ramos 4, Yan-Jun Zhang 5, Anastasia Ustyugova 6, Mark Lamotte 7
Affiliations(s): 1IQVIA, Real World Solutions, Zaventem 1930, Belgium. 2Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. 3Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. 4IQVIA, Global HEOR, Porto Salvo 2740-266, Portugal. 5Boehringer Ingelheim, Health Economics & Outcomes Research, Government Affairs & Market Access, Shanghai 200040, China. 6Boehringer Ingelheim, CardioMetabolism Respiratory, Ingelheim am Rhein 55216, Germany. 7IQVIA, Global HEOR, Zaventem 1930, Belgium.
Publication(s):  Journal of Comparative Effectiveness Research 2021 https://doi.org/10.2217/cer-2020-0284.
PMID: 33576249 DOI: 10.2217/cer-2020-0284
Document Type(s): Article,
Countries: China,
Click here for the abstract
C:
Y:
Diabetes, Health economics,
2021
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomisation studies
Author(s): Jonathan Pearson-Stuttard 1, Nikos Papadimitriou 2 3, Georgios Markozannes 2, Sofia Cividini 4, Artemisia Kakourou 2, Dipender Gill 5, Evangelos C Rizos 6 7, Grace Monori 5, Heather A Ward 5, Maria Kyrgiou 8 9, Marc J Gunter 3, Konstantinos K Tsilidis 2 5
Affiliations(s): 1Department of Epidemiology and Biostatistics, MRC-PHE Center for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. j.pearson-stuttard@imperial.ac.uk. 2Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. 3Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France. 4Department of Health Data Science, University of Liverpool, Liverpool, United Kingdom. 5Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. 6Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece. 7School of Medicine, European University of Cyprus, Nicosia, Cyprus. 8Department of Gut, Metabolism and Reproduction, and Surgery and Cancer, IRDB, Imperial College London, London, United Kingdom. 9West London Gynecological Cancer Center, Imperial NHS Trust, London, United Kingdom. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. IQVIA.
Publication(s):  PMID: 33737302 DOI: 10.1158/1055-9965.EPI-20-1245
Document Type(s): Article,
Countries: 
Click here for the abstract
C:
Y:
Diabetes,
2021
  L:
A:
English
Epidemiological study, Literature Review, Meta analysis,
  Add to report
 
 
Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the Ninth Mount Hood Diabetes Challenge
Author(s): Si L, Willis MS, Asseburg C, Tew M, Clarke PM, Lamotte M, Ramos M, Hui S, Shi L, Zhang P, McEwan P, Ye W, Herman WH, Isaman DJ, Kuo S, Schramm W, Sailer F, Brennan A, Pollard D, Smolen HJ, Leal J, Gray A, Patel R, Feenstra T, Palmer AJ
Affiliations(s): IQVIA, Zaventem, Belgium and IQVIA, Lisbon, Portugal
Publication(s):  Value in Health
Document Type(s): Article,
Countries: UK,
C:
Y:
Diabetes,
2020
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Contrasting three type 2 diabetes cardiovascular risk equations for east asia with ukpds82 using the IQVIA core diabetes model
Author(s): Ramos M1, Monteiro S2, Olivieri AV3, Lamotte M1
Affiliations(s): 1 IQVIA, Zaventem, Belgium 2 IQVIA, London, UK 3 IQVIA, Basel, Switzerland
Publication(s):  ISPOR US 2020 Orlando, Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB56
Document Type(s): Article,
Countries: Asia Pacific,
C:
Y:
Diabetes,
2020
  L:
A:
English
Population Based Study,
  Add to report
 
 
Impact of using different types of hba1c progression in the IQVIA core diabetes model
Author(s): Ramos M1, Monteiro S2, Lamotte M1
Affiliations(s): 1 IQVIA, Zaventem, Belgium 2 IQVIA, London, UK
Publication(s):  ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52
Document Type(s): Article,
Countries: UK,
C:
Y:
Diabetes,
2020
  L:
A:
English
Population Based Study,
  Add to report
 
 
Does including acute pancreatitis as a complication have an impact on cost-effectiveness analyses using the IQVIA core diabetes model?
Author(s): Monteiro S1, Ramos M2, Lamotte M2
Affiliations(s): 1 IQVIA, London, UK 2 IQVIA, Zaventem, Belgium
Publication(s):  ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52
Document Type(s): Article,
Countries: UK,
C:
Y:
Diabetes,
2020
  L:
A:
English
Population Based Study,
  Add to report
 
 
Cross-sectional survey in patients with type 1 and type 2 diabetes to understand mealtime insulin unmet needs in Japan: The MINUTES-J study
Author(s): Hitoshi Ishii 1, Suzuki Shuichi 2, Paul Williams 3, Sven Demiya 4, Toshihiko Aranishi 2, Tamas Treuer 5 (rwesheorj 4)
Affiliations(s): 1) Department of Diabetology, Nara Medical University, Nara, Japan 2) Eli Lilly Japan, K.K., Kobe, Japan 3) RWE Patient-Centered Endpoints Center of Excellence, IQVIA, Paris, France 4) IQVIA Solutions K.K., Tokyo Japan 5) Eli Lilly and Company, Budapest, Hungary
Publication(s):  Diabetes Research and Clinical Practice
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Diabetes,
2020
  L:
A:
English
Patient questionnaire,
  Add to report
 
 
Cost of Macrovascular Complications in People With Diabetes From a Public Healthcare Perspective: A Retrospective Database Study in Brazil
Author(s): Guilherme Silva Julian 1, Daniel Campos 1, Julie Broe Honore 2, Flávia Sauer Tobaruella 3, Jung Hyun Yoon 3, Nino Hallén 2
Affiliations(s): 1 IQVIA Brasil, São Paulo, Brazil. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Novo Nordisk Farmacêutica Do Brasil Ltda, São Paulo, Brazil.
Publication(s):  PMID: 32372710 DOI: 10.1080/13696998.2020.1764966
Document Type(s): Article,
Countries: Brazil,
Click here for the abstract
C:
Y:
Diabetes,
2020
  L:
A:
English
Observational study, Retrospective database analysis,
  Add to report
 
 
 1 of 61 Next Page Last Page